JAMP Pharma Group is active in all sectors of the pharmaceutical industry with our JAMP Pharma generic products, our Orimed Pharma branded products, our Wampole and Laboratoire Suisse natural health products, and our Cosmetic Import beauty and personal care products.
JAMP Pharma Group has also made a recent major investment in biosimilars—one of the fastest growing markets in the industry—with the launch of its BIOJAMP division.
For more than 33 years, we have been committed to supporting healthcare professionals so that they may focus on what matters most: the well-being of Canadians. We have made healthcare solutions more accessible and affordable for both patients and consumers.
As we look to the future, we are committed to ensuring that our diversified product portfolio remains accessible to all, while guaranteeing the most reliable supply in Canada.
Jason Frame Recognized by the Neighbourhood Pharmacy Association of Canada as Recipient of Distinguished Associate of the Year Award
Boucherville, June 7, 2022 – During the annual Pharmacy EXPO event in Toronto, the Neighbourhood Pharmacy Association of Canada (Neighbourhood Pharmacies) presented the Distinguished Associate of the Year Award to Jason Frame, Vice-President National Sales at JAMP Pharma. This award is tremendously meaningful to me because it represents a clear recognition of JAMP…
News and events, Press release
Biosimilar drugs: BIOJAMP(MC) and Accessa join forces to simplify access to Simlandi(MC)
Boucherville, April 27th 2022 – BIOJAMPMC, the new biosimilars division of Canadian pharmaceutical company JAMP Pharma Group, is proud to partner with Accessa, an initiative of the Association québécoise des pharmaciens propriétaires, to facilitate access to SimlandiMC, which is used to treat certain inflammatory diseases affecting the joints, skin, digestive…
JAMP Pharma Launches SIMLANDI™, a NEW High-Concentration, Low Volume, Citrate-Free formulation, Biosimilar to Humira®, in Canada
SIMLANDI™ provides patients access to high-concentration, low volume, citrate-free formulations of adalimumab, in 40 mg/0.4 mL and 80 mg/0.8 mL presentations, not available in Canada before this week SIMLANDI™ is the first adalimumab biosimilar product launched by a Canadian-based company, JAMP Pharma Group The creation of BIOJAMP™ Pharma…
New launches, Press release